The FDA advisory committee that met yesterday has recommended that Tamoxifen prescribing information now include mention of the possibility that the drug may be ineffectual for post-menopausal breast cancer survivors who carry the “poor metabolizer” CYP2D6 genotype. Here’s the story from the Chicago Sun Times.

Technorati Tags: breast cancer, tamoxifen, FDA, CYP2D6, poor metabolizer

This entry was posted on Thursday, October 19th, 2006 at 11:06 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.